Exploring the influence of baseline rheumatoid factor levels on TNF inhibitor retention rate in patients with rheumatoid arthritis: a multicentre and retrospective study

To assess whether the retention rate of certolizumab pegol (CZP) was longer than that of other tumour necrosis factor inhibitors (TNFi) based on baseline rheumatoid factor (RF) levels. Longitudinal, retrospective and multicentre study including patients with RA who were treated with any TNFi (monocl...

Descripción completa

Detalles Bibliográficos
Autores: López-Medina, Clementina, Calvo-Gutiérrez, Jerusalem, Ábalos-Aguilera, M Carmen, Cepas, Francisco, Plasencia-Rodríguez, Chamaida, Martínez-Feito, Ana, Balsa, Alejandro, Faré-García, Regina, Juan Mas, Antonio, Ruiz-Esquide, Virginia, Sainz, Luis, Díaz-Torné, César, Godoy-Navarrete, Francisco Javier, Añón-Oñate, Isabel, Mena-Vázquez, Natalia, Manrique-Arija, Sara, Moreno-García, Marina Soledad, Ortega-Castro, Rafaela, Escudero-Contreras, Alejandro
Tipo de recurso: artículo
Fecha de publicación:2024
País:España
Institución:Conselleria de Salut i Consum del Govern de les Illes Balears
Repositorio:Docusalut
Idioma:inglés
OAI Identifier:oai:docusalut.com:20.500.13003/20276
Acceso en línea:https://hdl.handle.net/20.500.13003/20276
Access Level:acceso abierto
Palabra clave:Rheumatoid Factor
Tumor Necrosis Factor Inhibitors
Arthritis, Rheumatoid
Etanercept
Antibodies, Monoclonal
Treatment Outcome
Humans
Retrospective Studies
Certolizumab Pegol
Inhibidores del Factor de Necrosis Tumoral
Resultado del Tratamiento
Humanos
Factor Reumatoide
Estudios Retrospectivos
Anticuerpos Monoclonales
Artritis Reumatoide
Descripción
Sumario:To assess whether the retention rate of certolizumab pegol (CZP) was longer than that of other tumour necrosis factor inhibitors (TNFi) based on baseline rheumatoid factor (RF) levels. Longitudinal, retrospective and multicentre study including patients with RA who were treated with any TNFi (monoclonal antibodies (mAB), etanercept (ETA) or CZP). Log-rank test and Cox regressions were conducted to evaluate the retention rate in the three groups according to the level of RF, with the third quartile of the baseline levels used as cut-off: <200 (<Q3) and ≥200 (≥Q3) IU/mL. A sensitivity analysis matching patients using a propensity score technique based on age, concomitant use of methotrexate and previous targeted synthetic/biological disease-modifying antirheumatic drugs was performed to address the imbalance across groups. A total of 638 individuals and 752 treatments (132 CZP, 439 mAB and 181 ETA) were included. In non-naïve patients with ≥200 IU/mL of RF, those treated with CZP showed a significantly longer retention rate in comparison with mAB and ETA. After matching using the propensity score, patients with ≥200 IU/mL RF levels exhibited longer retention rates with CZP than with mAB (HR 2.3 (95% CI 1.2 to 4.3), or ETA (HR 2.8 (95% CI 1.5 to 5.2). No differences were found between groups in patients with <200 UI/mL. CZP showed a longer retention rate than mAB and ETA in patients with very high RF levels (≥200 IU/mL), while these differences were absent in patients with <200 IU/mL levels. The results suggest the potential effect of RF on binding the fragment crystallisable portion of certain TNFi.

Similares en LA Referencia